Semax, a peptide derived from the adrenocorticotropic hormone (ACTH), has shown promise in preclinical studies for its potential therapeutic effects in treating anxiety disorders. The evidence supporting its use is based on several properties and mechanisms of action, including neuroprotection, immunomodulation, influence on gene expression related to vascular functioning, modulation of neurotransmitter systems, attenuation of chronic stress effects, and potential as a melanocortin antagonist [8].
What the AI assistants say
AI assistants collectively agree that Semax has shown preclinical support for anxiolytic-like and anti-stress effects, primarily in animal studies. They highlight several mechanisms through which Semax may exert its effects, including BDNF/TrkB upregulation, modulation of serotonergic and dopaminergic systems, melanocortin receptor interaction, enkephalinase inhibition, and HPA axis regulation. The AI assistants also note the limited evidence base, consisting mainly of animal studies, and the absence of human clinical trials specifically demonstrating Semax’s efficacy for anxiety. They mention that Semax is approved for other uses in Russia and Ukraine, but not for anxiety disorders.
What the research actually shows
The research supports the AI assistants’ claims by providing more specific details on the preclinical evidence for Semax’s potential use in treating anxiety disorders. Studies have shown that Semax promotes the survival of neurons during hypoxia and glutamate neurotoxicity, conditions often associated with anxiety disorders [8]. It also increases the amount and mobility of immune cells and enhances the expression of chemokine and immunoglobulin genes, suggesting immunomodulatory effects [8]. Furthermore, Semax influences the expression of genes that promote the formation and functioning of the vascular system, contributing to mitochondrial stability under stress induced by the deregulation of calcium ion flow, which could be relevant for anxiety disorders given the role of calcium signaling in anxiety [8].
Semax elevates the expression of brain-derived neurotrophic factor (BDNF) and the TrkB receptor, activates dopaminergic and serotonergic stems, and can work as an antidepressant and an anxiolytic [8]. It attenuates chronic stress effects and is a potential melanocortin antagonist (MC3R, MC4R), receptors that have been implicated in anxiety and stress responses [8]. By blocking these receptors, Semax may reduce anxiety-like behaviors. Additionally, Semax has been shown to combine well with the racetam family of nootropics, providing focused cognitive performance and focus without deleteriously affecting sleep or causing anxiety or jitters [16]. This suggests that Semax may have anxiolytic effects and could be used in combination with other compounds to treat anxiety disorders. Lastly, Semax works well when combined with the peptide Selank, which can simulate stimulants, tranquilizers, ADHD treatments, and antidepressants all at once, and is well-studied for cognitive recovery from strokes and can speed up recovery from traumatic brain injury (TBI) [16]. This indicates that Semax may have synergistic effects when used in combination with other peptides, potentially enhancing its anxiolytic effects.
Where the AI consensus and the research diverge
The AI assistants and the research corpus both agree on the preclinical evidence supporting Semax’s potential anxiolytic effects. However, the research corpus provides more specific details on the mechanisms of action and the nature of the preclinical studies, while the AI assistants provide a more general overview of the evidence. The research corpus also emphasizes the need for further clinical trials to establish the efficacy and safety of Semax in treating anxiety disorders.
Bottom line: Preclinical evidence suggests that Semax may have potential anxiolytic effects through various mechanisms, including neuroprotection, immunomodulation, and modulation of neurotransmitter systems, supporting its potential use in treating anxiety disorders. However, further research, including clinical trials, is necessary to fully establish the efficacy and safety of Semax in treating anxiety disorders.
References
- Anxious_ Using the Brain to Understand and Treat Fear and Anxiety
- Boundless Upgrade Your Brain, Optimize Your Body and Defy — Ben Greenfield
- Disease Prevention and Treatment
- Handbook of Biologically Active Peptides
- Inhibition of nucleo-cytoplasmic proteasome translocation by — Ido Livneh & Bertrand Fabre & Gilad Goldhirsh & Chen Lulu &
- Neuroprotective Effects of Tripeptides—Epigenetic Regulators — Khavinson, Vladimir (author)
- Neuroscience_ Exploring the Brain
- Peptide Protocols Volume One — William A Seeds MD
- Selenium_ Its Molecular Biology and Role in Human Health
- Signal Transduction in the Nervous System
- Textbook of Natural Medicine
- The Neurobiology of Pain
- The New Mind-Body Science of Depression — Vladimir Maletic, Charles Raison, Rhonda Patrick
Continue your research
Part of our Semax: Research Evidence & Trials guide.
- What clinical evidence supports the use of Semax in treating neurological disorders?
- What preclinical data support the use of Semax for cognitive enhancement?
- What clinical trials have been conducted to evaluate the efficacy of Semax in treating cognitive impairments?
Related topics:
- What are the potential benefits of Semax in treating psychiatric disorders?
- What are the potential benefits of Semax in treating neurodegenerative diseases?
- What are the potential side effects and safety concerns associated with Semax use?